Ebola breakthrough? new trial aims to stop virus after exposure
NCT ID NCT06841614
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a vaccine plus an antibody drug right after high-risk Ebola contact can prevent the disease better than the vaccine alone. About 160 people who have had close contact with an Ebola patient (like touching body fluids or a dead body) will be randomly assigned to one of two groups. The goal is to see which approach lowers the chance of getting sick.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guinea Centre for Research and Training in Infectious Diseases (CERFIG)
Conakry, Guinea
-
National Institute for Biomedical Research (INRB)
Kinshasa, Democratic Republic of the Congo
-
National Public Health Institute of Liberia
Monrovia, Liberia
-
University of Sierra Leone College of Medicine and Allied Health Sciences
Freetown, Sierra Leone
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ebola vaccine trial aims to shield frontline workers in congo
- Ebola vaccine in a nasal spray? early trial halted
- Ebola vaccine memory under the microscope: how long does it last?
- Could a vaccine and antibody combo stop ebola after exposure?
- UK volunteers test new ebola vaccine combo in Early-Stage trial
- Ebola antibody cocktail made available in emergency outbreak